Nevisense Go
Nevisense Go offers compact, wireless skin assessment technology for high-quality evaluations.

SciBase Holding develops point-of-care skin-health platforms, including Nevisense and Nevisense Go, which detect skin cancer.
scibase.comCrawled Nov 13, 2026
Nevisense Go offers compact, wireless skin assessment technology for high-quality evaluations.
The platform supports skin health applications, including early skin cancer detection and dermatological research.
Objective data for evidence-based skincare Nevisense provides cosmetic and product developers with accurate, reproducible measurements of how products affect the skin barrier – supporting product development, efficacy validation and claims support.
Melanoma is one of the most aggressive skin cancers. Nevisense supports dermatologists to improve accuracy and confidence in clinical decision-making.
From advanced clinical tools to portable solutions, SciBase offers products to elevate skin diagnostics and research, based on proprietary EIS and AI.
Nevisense enables objective, non-invasive skin barrier assessment of barrier function in both clinical and research settings. that track treatment efficacy
SciBase seeks individuals to contribute to medical diagnostics in a collaborative, research-focused environment.
SciBase’s leadership team includes expertise in medtech, dermatology, and business to support its growth and global development.
SciBase’s board provides strategic guidance with experience in medtech, healthcare, and business.
Following SciBase’s first U.S. private payer coverage, Pia Renaudin discusses what this milestone means for patients, clinicians, and the company’s ambitions.
SciBase develops skin diagnostics using advanced technology and clinical insight for accuracy, objectivity, and accessibility.
Nevisense integrates into clinical practice to support informed decision-making.
The company helps healthcare providers, researchers, partners, and customers locate representatives or Nevisense clinics.
Healthcare providers use Nevisense non-invasive technology for early detection and evaluation of skin conditions.
SciBase combines EIS technology and AI for earlier, more accurate skin condition diagnosis with Nevisense point-of-care solutions.
SciBase Holding AB reports a **41% year-over-year increase in Q3 net sales to SEK 14.6 million**, driven by US demand and recurring electrode sales. The company’s after-tax loss expands to **SEK 25.8 million**, up from SEK 18.2 million in the prior year. An auditor has raised **going-concern uncertainty**, signaling potential financial instability despite revenue growth.
SciBase completes a SEK 40.2 million rights issue, subscribing 2.68 million shares. The Board authorized the offering in May 2026, with subscriptions closing on September 29. The total proceeds fall short of the targeted SEK 57.5 million.
**Scibase enrolls the first patient in a multicenter study** evaluating early prediction of atopic dermatitis (AD) flares. The prospective clinical trial aims to assess flare forecasting in patients with this chronic inflammatory skin condition. Researchers are investigating biomarkers or tools to identify flare risks before symptoms appear, potentially improving treatment strategies for millions affected by AD.
SciBase has sold over 400,000 Nevisense tests, a non-invasive, FDA-approved and CE-marked diagnostic tool for dermatologists. The device evaluates suspicious moles and melanoma risk, enabling more precise clinical decisions. Nevisense delivers personalized risk assessments directly in healthcare settings.
SciBase, an AI-based dermatology device provider, sets the record date for its reverse share split, consolidating 100 existing shares into one. The decision follows the company’s Annual General Meeting held on May 19, 2026. The move aims to adjust share pricing amid market conditions.
SciBase collaborates with Castle Biosciences to create an AI-based diagnostic test predicting atopic dermatitis flare-ups. The solution leverages SciBase’s EIS technology for molecular analysis. The company also plans a directed share issue of approximately **30 million SEK** to support development.